Project Grant K08HL171874
- Federal Grant Award Summary Baylor College of Medicine received a $673,598 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion expected by June 30, 2029. The award funds research into cardiomyocyte-fibroblast signaling mechanisms in atrial fibrillation (AF), a condition affecting an estimated twelve million Americans by 2030 and contributing to at least...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $498,000 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 2, 2025, with a completion date of August 31, 2028. This grant supports research investigating the molecular determinants of atrial fibrillation (AF), the most common serious cardiac arrhythmia affecting an estimated 33.5 million...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Harvard College's Office for Sponsored Programs a Project Grant of $151,040 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research investigating the role of Tolloid (TLD) proteases in atrial fibrosis pathogenesis. The research aims to elucidate how TLD protease-mediated activation of Growth Differentiation Factor 11 (GDF11) regulates fibrotic processes in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $174,528 to the Regents of the University of Minnesota under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding August 31, 2030. This project grant supports translational research aimed at identifying novel therapeutic targets for atrial myopathy, a structural and functional condition of the atria that contributes to atrial fibrillation, heart failure, and...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 25, 2025, with completion targeted for July 31, 2028. The award funds research investigating the role of the transcription factor PITX2 (paired-like homeodomain transcription factor 2) in atrial fibrillation (AF) pathogenesis, specifically examining...
- Grant Award Summary The University of Utah received a $149,872 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 20, 2025, with completion targeted for January 5, 2027. The research project, titled "Myocarditis is Necessary for the Development of Arrhythmogenic Cardiomyopathy," investigates the mechanisms underlying arrhythmogenic cardiomyopathy (ACM), an inherited cardiac...
- Federal Project Grant Summary Weill Medical College of Cornell University received a $708,265 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award funds a mechanistic re-evaluation of fibroblast growth factor homologous factors (FHFs) in cardiac physiology and their role in life-threatening arrhythmias. The research will employ structurally...
- Federal Grant Award Summary Baylor College of Medicine received a $752,618 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 2, 2025, with a completion date of May 31, 2030. This award supports investigative research focused on elucidating the inflammatory mechanisms underlying postoperative atrial fibrillation (POAF), a common complication following cardiothoracic surgery affecting...
- Federal Project Grant Award Summary Dr. Sri Karthika Shanmugam received a K99/R00 career development award of $133,436 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through July 31, 2027. The award supports Dr. Shanmugam's transition to an independent academic research position at Columbia University's Health Sciences Division in New York. During the K99 phase, the award funds structured...
- Federal Grant Award Summary The University of California, San Francisco received a $125,703 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on July 28, 2025, with a completion date of March 31, 2030. The grant supports investigative research examining the role of SYNE1-GIANT protein in atrial cardiomyopathy, a condition affecting approximately 6 million Americans with atrial fibrillation (AF) and...
WNT SIGNALING IN THE PATHOGENESIS OF ATRIAL FIBRILLATION - PROJECT SUMMARY / ABSTRACT ATRIAL FIBRILLATION (AF) IS A COMMON SUSTAINED CARDIAC ARRHYTHMIA WITH ASSOCIATED RISKS THAT INCLUDE STROKE, HEART FAILURE, AND DEATH. DESPITE THE PUBLIC HEALTH BURDEN, OUR UNDERSTANDING OF THE PATHOPHYSIOLOGIC BASIS OF AF REMAINS INCOMPLETE, AND THIS IS REFLECTED IN THE LACK OF THERAPEUTIC ADVANCEMENT. THIS PROPOSAL AIMS TO LEVERAGE THE CLINICAL AND SCIENTIFIC EXPERTISE THAT DR. BAPAT HAS DEVELOPED THUS FAR TO EXPLORE A NOVEL PATHWAY IN AF, ALL WHILE ALLOWING HIM TO GROW AS A SCIENTIST UNDER THE DIRECT MENTORSHIP AND GUIDANCE OF TWO VERY ACCOMPLISHED PHYSICIAN SCIENTISTS. DR. BAPAT HAS PRODUCED SUBSTANTIAL DATA WORKING WITH MOUSE MODELS OF AF. HE CONTRIBUTED TO A RECENT PUBLICATION THAT IDENTIFIED MURINE DEFICIENCY OF ZFHX3, A GENE IMPLICATED IN HUMAN AF, AS PATHOLOGIC, LEADING TO ATRIAL ARRHYTHMIA, FIBROSIS, AND CONTRACTILE DYSFUNCTION. IN ADDITION, HE HAS EXTENSIVELY STUDIED MOUSE MODELS OF "ACQUIRED" AF RESULTING FROM OBESITY OR SEPSIS. IN EXCITING PRELIMINARY DATA, NON-CANONICAL WNT SIGNALING HAS BEEN NOTED TO BE UPREGULATED IN BOTH GENRES OF AF PATHOGENESIS. AS THE DOWNSTREAM CONSEQUENCES INCLUDE EFFECTS ON CALCIUM HANDLING, STRESS SIGNALING, INFLAMMATION, AND FIBROSIS, THERE IS A FEASIBLE BIOLOGICAL LINK THAT WARRANTS FURTHER EXPLORATION. IN ADDITION, DR. BAPAT HAS DEMONSTRATED THE EFFICACY OF INHIBITING SERUM GLUCOCORTICOID KINASE 1 (SGK1), WHICH LIES DOWNSTREAM TO NON-CANONICAL WNT SIGNALING, IN MODELS OF OBESITY- RELATED AF. THIS PROPOSAL'S OVERARCHING OBJECTIVE IS TO BETTER DEFINE THE ROLE OF NON-CANONICAL WNT SIGNALING IN VARIOUS MODELS OF AF AND THEN DETERMINE WHETHER INTERVENING ON THIS SIGNALING PATHWAY MAY BE PROTECTIVE. FIRST, DR. BAPAT PROPOSES TO EXPAND UPON OUR EXISTING UNDERSTANDING OF ZFHX3-DEFICIENCY RELATED ATRIAL PATHOLOGY BY ADDRESSING ANY POSSIBLE CONFOUNDING RELATED TO DEVELOPMENTAL EFFECTS. HE HAS GENERATED MICE WITH INDUCIBLE, CARDIAC-RESTRICTED ZFHX3 DEFICIENCY, AND WILL STUDY THEIR CARDIAC PHENOTYPE, WITH A PARTICULAR INTEREST ON WNT SIGNALING AND AF PROPENSITY. HE THEN WILL STUDY A MODEL OF SEPSIS-RELATED AF, GENERATED BY PERFORMING CECAL LIGATION AND PUNCTURE (CLP). PRELIMINARY DATA REVEALS AN UPREGULATION IN WNT SIGNALING AND SGK1 ACTIVATION, AND HE WILL ATTEMPT TO RESCUE ARRHYTHMOGENESIS WITH GENETIC SGK1 INHIBITION. FINALLY, HE WILL UTILIZE A MULTI-OMIC ASSAY TO UNDERSTAND THE TRANSCRIPTIONAL EFFECTS OF CLP ON ATRIAL TISSUE THAT MAY BE DRIVING ARRHYTHMOGENESIS. THIS WORK WILL TAKE PLACE IN THE CARDIOVASCULAR RESEARCH CENTER AT THE MASSACHUSETTS GENERAL HOSPITAL (MGH) AND AT THE BROAD INSTITUTE OF MIT AND HARVARD UNDER THE MENTORSHIP OF DR. PATRICK ELLINOR, THE CHIEF OF CARDIOLOGY AT MGH, AND DR. SAUMYA DAS, AN ASSOCIATE PROFESSOR AT HARVARD MEDICAL SCHOOL. DR. BAPAT'S GOAL IS TO BECOME AN INDEPENDENT BASIC SCIENTIST WITH EXPERTISE IN THE MECHANISTIC BASIS FOR CARDIAC ARRHYTHMIAS. HE IS DEDICATED TO BECOMING AN INDEPENDENT INVESTIGATOR AND TO USE THE RESEARCH PERFORMED FOR THE K08 AS A SPRINGBOARD FOR AN R01 APPLICATION IN THE FUTURE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $170.2k | 8/25/25 | ||
| Not listed | $170.0k | 7/31/24 |